Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD) therapies, will participate in a fireside chat at the UBS Virtual TPD Day.
The event is scheduled for July 15, 2024, at 1:00 p.m. ET. A live webcast of the presentation will be accessible on the company's website under the 'News and Events' section in the Investors area. An archived replay will be available post-event.
- None.
- None.
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET.
A live webcast of the presentation will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (previously Twitter) or LinkedIn.
| Investor and Media Contact: Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com media@kymeratx.com 857-285-5300 |
FAQ
When will Kymera Therapeutics present at the UBS Virtual Targeted Protein Degradation Day?
What is the stock symbol for Kymera Therapeutics?
Where can I watch the live webcast of Kymera Therapeutics' presentation?
Will there be a replay available for Kymera Therapeutics' presentation at the UBS Virtual TPD Day?
What type of medicines is Kymera Therapeutics developing?
